HYPE: High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study

Sponsor
Dana-Farber Cancer Institute (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05740839
Collaborator
Stahl Family Charitable Foundation (Other), The Childhood Brain Tumor Foundation (Other), Pedals For Pediatrics (Other)
30
1
2
13
2.3

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether a 16-week virtual, home-based, high-intensity interval training (HIIT) exercise program will improve physical, cognitive, and emotional health among young adult survivors of pediatric brain tumors.

The names of the study interventions involved in this study are/is:
  • High-Intensity Interval Training (HIIT)
Condition or Disease Intervention/Treatment Phase
  • Behavioral: HIIT Exercise Program
  • Behavioral: Control Group
N/A

Detailed Description

This is a Pilot/Feasibility, randomized control, research study that will compare an exercise group to a control group on physical, social, and overall quality of life needs of pediatric brain tumor survivors who are now young adults.

Participants will be randomized (selected at random) for two groups: HIIT program group will complete a 16-week intervention period followed by a 16-week period with no intervention and the waitlisted control group will complete a 16-week period and will perform their usual, daily activities followed by an optional 16-week period in which they can complete the HIIT program.

Research procedures include screening for eligibility, study treatment including in-clinic evaluations of fitness and strength, blood collection, at-home zoom exercise sessions, self-administered activity logs, and survey questionnaires.

Participation in this research study is expected to last about 8 months.

It is expected that about 30 people will take part in this research study.

The Stahl Family Charitable Foundation, Pedal 4 Pediatrics, and the Childhood Brain Tumor Foundation are supporting this research study by providing funding for the study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study (HYPE)
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Jan 31, 2024
Anticipated Study Completion Date :
May 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: HIIT Exercise Program Group

Participants will be randomly assigned to the HIIT exercise group and receive: 3x weekly for 16 week home-based virtually supervised High-Intensity Interval Training. 16-week self-directed exercise follow up period. 3 On-site visits at Week 1, 18 and 34 for assement testing and completion of questionnaires

Behavioral: HIIT Exercise Program
Exercise program with stationary bike via the Zoom platform.
Other Names:
  • High-Intensity Interval Training
  • Active Comparator: Control Group

    Participants will be randomly assigned to the HIIT waitlist control group and receive: Daily usual activities 2 On-site visits at Week 1, and 18 for assement testing and completion of questionnaires Option to complete 16 week, 3x weekly HIIT exercise program after initial 16 week period.

    Behavioral: Control Group
    Usual Activities

    Outcome Measures

    Primary Outcome Measures

    1. Attendance of Exercise Sessions [From first exercise session to final exercise session, up to 16 weeks]

      Defined as participant attendance of >= 70% of the 48 HIIT exercise sessions.

    2. Completion in Minutes of Exercise Sessions [From first exercise session to final exercise session, up to 16 weeks]

      Defined as participant completion of >= 70% of the 90 minutes of exercise per week

    3. HIIT Compliance [From first exercise session to final exercise session, up to 16 weeks]

      Defined as obtaining +-5W of target power output for >= 40 seconds of high intensity minute

    4. Barriers to Exercise Adherence [From first exercise session to final exercise session, up to 16 weeks]

      Assessed through the 17-item Barriers to Recruitment Participation Questionnaire (BRPQ), 1-5 scale with 1 denoted as strongly agree and 5 as strongly disagree.

    5. Participant Burden [From first exercise session to final exercise session, up to 16 weeks]

      Assessed through the Perceived Research Burden Assessment (PRBA), 1-5 scale with 1 denoted as strongly disagree and 5 as strongly agree.

    Secondary Outcome Measures

    1. Cognition [: From baseline to post-intervention, up to 43 weeks]

      An assortment of tests will be executed through the NIH toolbox to measure overall cognition.

    2. Cardiorespiratory Fitness [From baseline to post-intervention, up to 43 weeks]

      Assessed through the use of a VO2 max (or submaximal if equipment is unavailable) cycle exercise stress test (Parvo Medics TrueOne 2400; Sandy, UT, USA).

    3. Muscular Strength [From baseline to post-intervention, up to 43 weeks]

      10-repetition maximum will be used to assess muscular strength.

    4. Body Composition [From baseline to post-intervention, up to 43 weeks]

      Bioelectrical Impedance Analysis (BIA), and blood pressure as measured twice on both arms with a seated position with a minimum of 1-minute interval and the higher pressure will be recorded when there are differences. BIA: Assessed via bioelectrical impedance using a validated device (Tanita 780, Arlington Heights, IL). Participants will be asked to remove their shoes and socks after which height will be taken using a stadiometer they will then proceed to move to the BIA and stand still on the device while holding the handles with their hands at their sides. The device will estimate body fat using an algorithm based on their age, sex, height, and body weight.

    5. Fatigue [From baseline to post-intervention, up to 43 weeks]

      BFI: A questionnaire of scale ratings 0 - 10 that focuses on cancer-related fatigue and tiredness.

    6. Psychosocial Health [From baseline to post-intervention, up to 43 weeks]

      Assessed through the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire, which is comprised of 27 items with scale ratings validated to measure physical, emotional, social, and functional well-being of cancer patients and survivors

    7. Quality of Sleep [From baseline to post-intervention, up to 43 weeks]

      Assessed through the Pittsburg Sleep Quality Index (PSQI), which is used to measure 7 components of the quality and patterns of sleep in participants.

    8. Dietary Assessment, ASA-24 [Up to 3 days]

      Participants will be provided with a login to enter dietary data measured by an automated, online self-administered 24-hour assessment tool.

    9. ActiGraph - Physical Activity Monitoring [From baseline to post-intervention, up to 27 weeks]

      Participants will be provided with an accelerometer (ActiGraph, Pensacola, FL) to wear for seven days at baseline and post-intervention testing visits and will be instructed to wear the water-resistant accelerometer at all times except for when swimming or bathing. The device will record activity data and will be electronically transferred to a computer via USB cable at time of completion.

    10. Exercise Tolerance [From baseline to week 16, up to 32 weeks]

      Will be recorded using the Exercise-Induced Feeling Inventory (EIF). Based on a 0-4 scale, it assesses the participant's feeling state change(s) post-exercise and is also used for the assessment of self-motivation to adhere to an exercise regimen. Participants will be asked to complete the inventory before and after each exercise session.

    11. Pain Index [From baseline to post-intervention, up to 43 weeks]

      BPI: A 9 item questionnaire to evaluate the severity of pain and the impact of pain on the participant's daily functioning.

    12. Hip and Waist Circumference [From baseline to post-intervention, up to 43 weeks]

      Hip and waist circumference will be assessed and recorded in cm.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 39 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Written informed consent prior to any study-related procedures.

    • At time of study are a young adult, aged 18-39 years.

    • Histologically diagnosed brain tumor during childhood (diagnosed ≤18 years).

    • Are at least 2 years post tumor-directed therapy.

    • The effects of exercise on the developing fetus are unknown. For this reason, women of child-bearing potential must agree to undergo a pregnancy test and to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately.

    • Medically cleared to participate in exercise by their referred physician or a certified clinical exercise physiologist.

    • Are without medical conditions that could exacerbate with exercise, such as bone disease (excluding bone metastases) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases.

    • Speak English and/or Spanish.

    • Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise/week.

    • Does not smoke or vape (no smoking/vaping during previous 12 months).

    • Willing to travel to DFCI for necessary data collection.

    • Ability to understand and the willingness to sign a written informed consent document.

    Exclusion Criteria:
    • Diagnosis of primary spinal cord tumor.

    • Pre-existing medical conditions such as uncontrolled cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise.

    • Patients with active malignancies.

    • Patients who are pregnant.

    • Actively on a weight loss diet.

    • Participate in more than 60 minutes of moderate or vigorous structured exercise/week.

    • Currently smokes or vapes.

    • Unable to travel to DFCI for necessary data collection.

    • May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dana Farber Cancer Institute Boston Massachusetts United States 02215

    Sponsors and Collaborators

    • Dana-Farber Cancer Institute
    • Stahl Family Charitable Foundation
    • The Childhood Brain Tumor Foundation
    • Pedals For Pediatrics

    Investigators

    • Principal Investigator: Christina Dieli-Conwright, PhD, MPH, Dana-Farber Cancer Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Christina Dieli-Conwright, PhD, Principal Investigator, Dana-Farber Cancer Institute
    ClinicalTrials.gov Identifier:
    NCT05740839
    Other Study ID Numbers:
    • 22-505
    First Posted:
    Feb 23, 2023
    Last Update Posted:
    Feb 23, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Christina Dieli-Conwright, PhD, Principal Investigator, Dana-Farber Cancer Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 23, 2023